276 results about "Bile acid" patented technology

The present invention discloses a Lactobacillus plantarum and its application in the preparation of functional preparations for preventing and treating inflammatory bowel disease, as well as antioxidant, anti-inflammatory and antibacterial functions. It has excellent ability to scavenge reactive oxygen species, as well as good probiotic characteristics such as acid tolerance, bile salt tolerance, hydrophobicity, self-aggregation ability and inhibition of common human pathogenic bacteria. At the same time, it can improve intestinal inflammation, has a preventive and therapeutic effect on inflammatory bowel disease, and has high biological safety. It can be used as a probiotic preparation to relieve inflammatory bowel disease, improve intestinal mucosal damage and colon inflammation, providing a new strategy for the prevention and treatment of inflammatory bowel disease and having potential clinical application prospects.

The invention belongs to but is not limited to the technical field of biomedicine, and discloses application of golden amide alcohol ester to preparation of a medicine for treating cholestasis. The in-vitro cell level verifies that the golden amide alcohol ester has relatively strong activity of activating FXR and CAR. The golden amide alcohol ester can relieve the cholestasis symptom of a cholestasis model mouse. The golden amide alcohol ester can obviously reduce the content of total bile acid and bilirubin in cells, relieve cholestasis and relieve hepatocyte damage. The golden amide alcohol ester can regulate and control the protein level of transporters and metabolic enzymes related to bile acid and bilirubin through double excitation of FXR and CAR, relieve cholestasis and achieve the purposes of benefiting gallbladder and removing jaundice.

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

The invention belongs to the technical field of feed additives, and particularly relates to slow-release fat powder for pigs and a preparation method of the slow-release fat powder. The slow-release fat powder for pigs comprises an intragastric adhesion-slow release layer, a small intestine forepart bile acid response controlled release layer and a small intestine posterior microbe response controlled release layer. The prepared slow-release fat powder for the pigs is good in stability, accurate release of different nutritional ingredients in different parts of gastrointestinal tracts of the pigs can be achieved, and powerful support is provided for sustainable development of the pig raising industry.

The invention provides a water-blocking microcapsule, a fish oil composite hair beautifying ointment and a preparation method, and relates to the technical field of animal health products. The water-blocking microcapsule is a solid particle formed by a core material and a wall material coating the core material; the core material is fish oil emulsion subjected to bile salt emulsification treatment; the wall material sequentially comprises an inner-layer wall material and an outer-layer wall material from inside to outside; the inner-layer wall material is a wall material formed by solidifying alginate; and the outer-layer wall material is a water-blocking wall material which is arranged outside the inner-layer wall material and is made of nanocrystalline cellulose. The water-blocking microcapsule provided by the invention realizes multiple beneficial effects of efficient digestion and absorption of fish oil, improvement of palatability, enhancement of oxidation resistance and stability, fixed-point release of intestinal tracts and the like, provides an innovative technical scheme for development of animal health products, and has wide application prospects and market values.

The invention discloses emblic leafflower fruit polysaccharide with sugar-controlling and lipid-lowering activity as well as a preparation method and application of the emblic leafflower fruit polysaccharide. The polysaccharide is prepared by taking fresh phyllanthus emblica pulp as a raw material through hot water extraction, yeast fermentation, desorption after XAD-16 macroporous resin adsorption, alcohol precipitation, ultrafiltration and DEAE-52 cellulose column purification. The low-molecular-weight gulcomannan is separated from phyllanthus emblica for the first time, and monosaccharide composition of the gulcomannan mainly comprises glucose, mannose and galactose and contains trace rhamnose and xylose. The polysaccharide has sugar-controlling and lipid-lowering active action targets in the whole digestive tract (the upper digestive tract: glycolipid digestion and absorption enzymes alpha-amylase, alpha-glucosidase and pancreatic lipase inhibitory activity, starch hydrolysis delay, bile acid adsorption capacity and cholesterol micelle dissolution inhibition capacity; in the lower digestive tract, the multiplication promoting capacity of glycolipid metabolism-related probiotics) shows extremely high biological activity, and can be applied to food and health care products.

The invention discloses lactobacillus plantarum YBE2 and application thereof.According to the lactobacillus plantarum YBE2 for high yield of extracellular polysaccharide mainly containing rhamnose, different cholate types can be degraded at the same time, glycocholic acid is specifically hydrolyzed, and the lactobacillus plantarum YBE2 has the effects of lowering cholesterol and relieving acute inflammation at the same time. Meanwhile, the plant lactobacillus YBE2 can reduce the deposition of fat in the belly of the cage rearing broiler chicken, improve intramuscular fat, promote the deposition of fatty acid in muscles, reduce the total bile acid of plasma, triglyceride and low-density lipoprotein cholesterol, and remarkably improve the lipid metabolism and muscle quality of meat poultry, and can be widely applied to the breeding of the cage rearing broiler chicken, promote the healthy breeding of the meat poultry and improve the quality of the meat poultry. The culture benefit is improved.

The invention discloses Pediococcus pentosaceus G41, which is separated from rumen fluid of healthy adult dairy cows in a certain cattle farm in Changchun, has the advantages of high growth speed and strong acid production capacity, and can effectively relieve cholestatic liver injury. Experiments prove that the Pediococcus pentosaceus G41 reduces the activity of serum AST, ALT and GDH of a mouse with cholestatic liver injury, reduces the content of total bile acid in blood and liver, increases the content of total bile acid in excrement, and improves cholestatic and dirty injury caused by cholestatic.

The invention relates to a composition for treating large yellow croaker pyramidoniasis as well as a preparation method and application thereof, and belongs to the technical field of aquaculture. The composition comprises the following components: curcumin, bile acid, beta glucan, bacillus subtilis freeze-dried powder, marine red yeast freeze-dried powder, vitamin C, vitamin E and ethylicin. When the feed additive is added into basal feed to feed large yellow croakers infected with the trypanosomiasis, the death rate of sick fishes can be effectively reduced, the polypide loading capacity is remarkably reduced, and pathological injuries of livers and spleens of the large yellow croakers are relieved. In addition, the composition can also improve the non-specific immunity of the fish body, improve the liver function, enhance the antioxidant capacity of the liver, and improve the lipase activity of the intestinal tract at the same time. Therefore, the composition can be used as a medicine or a feed additive for treating the large yellow croaker pyramidoniasis, has the advantages of small dosage and remarkable effect, and provides a new technical approach for solving the problem that the current large yellow croaker pyramidoniasis lacks an effective prevention and control means.

The invention discloses a Min pig source lactobacillus reuteri LRM2293 strain and an application of the Min pig source lactobacillus reuteri LRM2293 strain in anti-inflammatory reaction. The Min pig source lactobacillus reuteri is named as Lactobacillus reuteri LRM2293, and is preserved in the China Center for Type Culture Collection, the address is Wuhan University, Wuhan, China, the preservation number is CCTCC NO: M 20242331, and the preservation time is October 25, 2024. Research finds that the lactobacillus reuteri LRM2293 has the capacity of transforming bile acid in vitro and can be used as a candidate strain of probiotics. In vitro, a culture supernatant of the lactobacillus reuteri LRM2293 can be used for reducing the inflammatory reaction of IPEC-J2 cells; in vivo, the LRM2293 strain can be colonized in each intestinal segment of a piglet, and can repair an intestinal barrier and relieve intestinal injury of the inflammatory piglet, so that the problem of antibacterial drug resistance caused by abuse of antibiotics is expected to be reduced, and a technical means is provided for development of a novel functional product.

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

The invention relates to the technical field of aquaculture, in particular to a preparation method and application of seawater larval fish biological bait. The preparation method comprises the following steps: mixing schizochytrium limacinum powder, bile acid and sunflower phospholipid according to a mass ratio of 50: (10-20): (10-20) to obtain the nutrition enhancer; diluting the nutrition enhancer until the concentration is 40g / t-50g / t, so as to obtain a diluent; adding 130-150 common rotifers into each milliliter of diluent, culturing for 12-18 hours, and collecting strengthened rotifers; 30-50 common artemia is added into each milliliter of the diluent, culturing is carried out for 12-18 hours, and reinforced artemia is collected; the combination of the strengthened rotifer and the strengthened artemia is the larval fish biological bait. The larval fish biological bait prepared by the invention is uniform in fry specification and high in survival rate in a bait transfer period, and has remarkable economic and ecological benefits.

The present invention relates to the application of saliva combined with lactobacillus in the preparation of a drug for treating obesity, and belongs to the field of biomedicine technology. The present invention provides the application of saliva combined with lactobacillus XA-1416 in the preparation of a drug for preventing and / or treating obesity, or preventing and / or treating obesity-related diseases. This strain can inhibit the weight gain of mice with obesity model induced by high-fat diet, reduce the blood lipid level of mice with obesity model induced by high-fat diet, improve the liver damage index of mice with obesity model induced by high-fat diet, reduce the area of ​​white fat cells in mice with obesity model induced by high-fat diet, promote the conversion of intestinal conjugated bile acid to free bile acid in mice with obesity model induced by high-fat diet, increase the level of intestinal FXR antagonist in mice with obesity model induced by high-fat diet, improve the intestinal flora imbalance of mice with obesity model induced by high-fat diet, inhibit fat accumulation in Hep G2 model, and inhibit differentiation into adipocytes in 3T3-L1 model.

The invention belongs to the technical field of disease medicine preparation, and particularly relates to nanocellulose, a preparation method thereof and application of the nanocellulose to reduction of bile acid level. The nano-crystalline cellulose is nano-crystalline cellulose fiber or nano-crystalline cellulose crystal; wherein the nano-crystalline cellulose fibers are in a slender whisker shape, the average length of the nano-crystalline cellulose fibers is 250-400 nm, and the nano-crystalline cellulose fibers are partially gathered and wound; the nanocellulose crystal is in a short rod crystal shape, the surface of the nanocellulose crystal is connected with a sulfuric acid half ester group, and the length of the nanocellulose crystal is 50-200 nm. The nanocellulose provided by the invention can achieve the purpose of treating intrahepatic cholestasis in the gestation period by improving the TBA level and improving the filial generation live birth rate; the traditional Chinese medicine composition has no obvious influence on liver and kidney functions, blood sugar, blood fat and the like, and is high in safety; in addition, the nanocellulose does not have potential target organ poison or accumulative effect, the biological safety performance is improved, and the nanocellulose can be used for a long time and is suitable for special crowds during pregnancy.

The invention belongs to the technical field of fermentation and metagen preparations, and particularly relates to application of bifidobacterium breve metagen in the aspects of scavenging free radicals and relieving oxidative aging. According to the present invention, the oxidative free radical scavenging experiment results show that the bifidobacterium breve NKU BB 1-2 metagen has good oxidative free radical scavenging ability, and has good scavenging ability on hydroxyl free radicals, superoxide anions and DPPH free radicals; meanwhile, through component analysis, it is found that the bifidobacterium breve NKU BB 1-2 metagen contains various antioxidant and anti-aging bioactive substances such as flavonoids, indoles, amino acids, bile acids and ceramides; a cell model experiment verifies that the bifidobacterium breve NKU BB 1-2 metagen can obviously relieve oxidative damage to the cells and improve the oxidation resistance of the cells, so that oxidative aging is relieved.

The invention belongs to the technical field of biological medicine, and discloses a dry blood spot liquid chromatography-mass spectrometry detection method adaptive to 7 metabolites. According to the method, a pH / polarity double-trigger microcapsule solvent carrier system is adopted, high-polarity extraction solvents, medium-polarity extraction solvents and low-polarity extraction solvents are packaged in the pH / polarity double-trigger microcapsule solvent carrier system in a layered mode, the solvents are released in sequence according to local pH and polarity changes in the extraction process, and amino acid, acyl carnitine, organic acid, bile acid, steroid, fatty acid and glycometabolism intermediate products are efficiently extracted respectively. The method disclosed by the invention breaks through the inherent limitation of a traditional static solvent system, solves the problem of unbalanced recovery rate caused by insufficient solvent suitability in dry blood spot extraction of seven metabolites with great polarity span, and remarkably improves the accuracy, reproducibility and coverage range of a DBS-LC-MS / MS platform in synchronous detection of multi-component metabolites; and reliable technical support is provided for newborn inherited metabolic disease screening, endocrine disease diagnosis and drug metabolism research.

This invention belongs to the field of bile acid detection technology, and discloses a sample pretreatment method for determining the content of bile acid subtypes and its application. The pretreatment method includes the following steps: S1, acidifying the sample to be tested with an acidifying agent to a pH of 2-4 to obtain an acidified sample; S2, eluting the acidified sample onto a mixed-mode anion exchange column to obtain an eluent; S3, evaporating the eluent and reconstituted with a rehydration solution to obtain the test sample. The test sample obtained by this pretreatment method can effectively eliminate or compensate for matrix interference when used for targeted analysis of bile acid subtypes by LC-MS / MS, thus effectively improving detection sensitivity.

The invention relates to the technical field of aquaculture feed, and provides a compound feed additive for improving fish sugar utilization rate and promoting growth, the compound feed additive comprises the following raw materials by weight: 0.1-0.14 part of chromium picolinate, 1.5-2.5 parts of vitamin C, 20-40 parts of amylase, 20-40 parts of protease, 10-20 parts of dimethyl-beta-propiothetin, 2-4 parts of bile acid, and 18-22 parts of a carrier. The compound feed additive provided by the invention has the beneficial effects that the blood sugar is regulated, and the sugar metabolism capability of fish bodies is improved; due to the use of the compound feed additive, energy supply caused by protein decomposition is reduced, so that the growth performance of the fishes and the utilization rate of the feed are improved; the low-temperature stress resistance of the fishes is improved, and the breeding negative influence caused by temperature change is reduced; the protein loss is reduced; the feed cost is reduced; and the culture benefit is improved.

The present invention provides means with which bile acids, phenols, indoles and organic acids contained in a sample can be stably preserved without cryopreservation of the sample. A sample preservation solution of the present invention is a sample preservation solution used for analyzing at least one component selected from the group consisting of bile acids, phenols, indoles and organic acids contained in a biological or environmental sample, containing at least the following (A) and (B): (A) condensed phosphate or polyoxyethylene sorbitan alkylate; and (B) guanidinium thiocyanate, Tris-HCl (pH 7 to 9), and EDTA.

The application relates to the technical field of medical detection, in particular to a detection kit for total bile acid and a detection kit for total bile acid. The application adds polyoxyethylene-polyoxypropylene copolymer, Span 40 and oxide in R1, and adds EDTA-Na2 and sodium bicarbonate in R2, so that the stability and precision of reagents are effectively improved, and the situation that a negative value is generated in the detection process is solved.

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

A GCPII inhibitor comprising 2-(phosphonomethyl)pentanedioic acid (2-PMPA) conjugated to a bile acid, and its use for treating diseases or conditions associated with elevated GCPII levels, such as inflammatory bowel disease.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

To provide an acid resistant powder excellent in processing stability, storage stability, pressure resistance, and bile acid resistance.SOLUTION: An acid-resistant powder contains primary coated particles, which are coated with a primary coating material (B) as a continuous phase including powder particles of a core material (A) and secondary coated particles having a structure where the primary coated particles are coated with a secondary coating material (C) as a single nucleus. The core material (A) contains a powder (A1) that includes viable bacteria with a bulk density of 0.2 to 0.7 and an excipient (A2) with a bulk density of 0.7 to 1.0, the primary coating material (B) contains lipids with a melting point of 40°C to 70°C, the secondary coating material (C) contains lipids with a melting point of 40°C to 100°C, an average particle diameter of the primary coated particles is between 50 μm and 500 μm, and the average particle diameter of the secondary coated particles relative to the average particle size of the primary coated particles is 1.05 to 2.0 times.SELECTED DRAWING: Figure 2

The application discloses a compound, a preparation method and a use for preparing a derivatization reagent, and belongs to the field of chemistry. The application claims a compound TMT-mAla-PP with a novel chemical structure and a preparation method and a use thereof. Compared with the same compound TMT-PP or TMT-Pro-PP in the prior art, the derivatization product obtained by using the TMT-mAla-PP provided by the application as a derivatization reagent for performing a derivatization reaction on a bile acid compound has a significantly better mass spectrometry response sensitivity. Therefore, the compound provided by the application can be used for preparing a derivatization reagent for a bile acid compound, and the derivatization reagent can perform derivatization modification on the bile acid compound before mass spectrometry detection of the bile acid compound, so that the detection performance of the mass spectrometry on the bile acid compound is significantly improved.

The invention provides a preparation method of a cholestatic liver injury animal model, which comprises the following steps: on the basis that a mouse is fed with a feed containing 500IU / kg vitamin A for 8 weeks to cause deficiency of vitamin A in the mouse body, performing intragastric administration of alpha-naphthyl isothiocyanate (ANIT) at 50mg / kg for 4 weeks once a week, so as to obtain the cholestatic liver injury mouse model. The blood biochemical index ALT, the liver index, the pathological structure change of the liver tissue and the bile acid deposition of the liver tissue are more obvious. The cholestatic liver injury model prepared by the preparation method can avoid the influence of inconsistent dosage and unstable model in a conventional method, and can be applied to the research fields of molecular mechanism research of occurrence and development of cholestatic liver injury, finding of cholestatic liver injury treatment medicines and methods and the like.

The invention discloses a traditional Chinese medicine composition and application thereof in medicine for improving non-alcoholic fatty liver, and the traditional Chinese medicine composition comprises pulvis fellis suis, pericarpium citri reticulatae, hawthorn and clostridium butyricum. On one hand, potential targets and pathways of drug diseases are determined in network pharmacological analysis, and on the other hand, in an in-vivo experiment, the drug provided by the invention improves obesity and impaired glucose tolerance caused by HFD, reduces the blood fat level, alleviates inflammation, protects the liver, alleviates liver fat vacuole deposition and fatty degeneration, and has a good application prospect. It is proved that the bile acid-hawthorn and pericarpium citri reticulatae-clostridium butyricum combination has prevention and treatment and protection effects on the HFD-induced non-alcoholic fatty liver disease.

The invention provides rhizoma alismatis purified polysaccharide as well as a preparation method, an identification method and application thereof, the rhizoma alismatis purified polysaccharide is a functional component with a novel structure in a traditional Chinese medicine rhizoma alismatis water extract obtained by further extraction and purification, the administration efficiency is effectively improved, and the pharmacodynamic substances are clarified; in-vivo and in-vitro experiments show that the polysaccharide can improve the antioxidant capacity of the liver and relieve inflammatory response; synthesis and metabolism of liver bile acid can be adjusted, cholestasis of the liver is relieved, and bile acid circulation is promoted so as to relieve acute liver injury caused by acetaminophen; the effect of promoting the recovery of liver injury patients is obvious; and the compound also can be used as prebiotics to improve the homeostasis of intestinal microorganisms and promote the synthesis of short-chain fatty acids so as to have beneficial effects on the liver.

The present invention addresses the problem of: developing a method capable of noninvasively sampling and analyzing intestinal mucosa bacteria; analyzing the intestinal bacteria, especially intestinal mucosa bacteria on the basis of the method; and developing a therapeutic method for diseases occurring in the intestinal tract for which therapeutic methods have not been established.　The inventors of the present invention have found that bacteria contained in a cotton swab (swab) sample on the feces surface exhibit a bacterial flora composition similar to that of bacteria existing in the intestinal mucosa; and, as a result of analysis based on the finding, have clarified that Adlercreutzia, which has not been reported until now as a mucosa-related bacterium, lives in the large intestinal mucosa layer, produces taurine, which is a strong anti-inflammatory compound, by the action of the bile acid-deconjugating enzyme, and alleviates enteritis, thereby completing the present invention. In other words, the present invention can provide a composition having an anti-inflammatory effect, which includes a bacterium of the genus Adlercreutzia, or a bile acid-deconjugating enzyme that is derived from a bacterium of the genus Adlercreutzia.